Patent Oppositions in metabolic drugs industry

Explore the competitive field of metabolic drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in metabolic drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Aug 27, 2026
CompanyTotal Oppositions
NOVARTIS182
BOEHRINGER INGELHEIM117
NOVO NORDISK91
BRISTOL MYERS SQUIBB59
NUTRICIA53
F HOFFMANN LA ROCHE52
AMGEN45
CELGENE38
NESTLE37
PFIZER33

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the metabolic drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the metabolic drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSAug 19, 2026WITHERS & ROGERS
Methods For Treating Cancer With Anti-Pd-1 AntibodiesMERCK SHARP & DOHMEAug 17, 2026WUESTHOFF & WUESTHOFF
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSAug 17, 2026LUMARA BIO ONCOLOGICS
Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]UreaPFIZERAug 16, 2026ELKINGTON AND FIFE
Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or HyperglycemiaBOEHRINGER INGELHEIMAug 13, 2026TEVA PHARMACEUTICAL INDUSTRIES LTD
Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)BenzamideACERTA PHARMAAug 11, 2026KRAUS & WEISERT
Crystal Forms Of 6-(Cyclopropanecarboxamido)-4-((2-Methoxy-3-(1-Methyl-1H-1,2,4-Triazol-3-Yl)Phenyl)Amino)-N-(Methyl-D3)Pyridazine-3-CarboxamideBRISTOL MYERS SQUIBBAug 11, 2026HAMPTON KNOWLES
Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or HyperglycemiaBOEHRINGER INGELHEIMAug 10, 2026BARDEHLE PAGENBERG
Nutritional ProductUCL BUSINESSAug 7, 2026MOLNIA
A Myostatin Pathway Inhibitor In Combination With A Glp-1 Pathway Activator For Use In Treating Metabolic DisordersSCHOLAR ROCKAug 6, 2026J A KEMP

To stay ahead in the competitive metabolic drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the metabolic drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS26
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY24
Aug 6, 2025Use Of Long-Acting Glp-1 PeptidesNOVO NORDISK18
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM18
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE17
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI MATURE15
Sep 17, 2025Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECA14
Jan 7, 2026Formulations Of EnzalutamideASTELLAS PHARMA14
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12
Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL MYERS SQUIBB11